Metabolic Syndrome and Ischemic Heart Disease in Gout

Vázquez‐Mellado, Janitzia; García-García, Conrado; Vázquez, Silvia Guzmán; Medrano, Gabriel; Ornelas, Mario; Alcocer, Luis; Márquez, Alfredo; Burgos‐Vargas, Rubén

doi:10.1097/01.rhu.0000129082.42094.fc

Cited by 60 publications

(41 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, the prevalence is substantially higher than among those who experienced myocardial infarction or stroke (41-44%) in the same NHANES study (18). These data expand on previous studies that demonstrated a close relationship between hyperuricemia and insulin resistance syndrome (6,9,10), and on the recent case series of gout and metabolic syndrome (12,13), thereby supporting a pathogenetic overlap between these conditions. Higher insulin levels are known to reduce renal excretion of urate (11,19 -21).…”

Section: Discussionsupporting

confidence: 79%

“…Therefore, the reduced renal excretion of urate among patients with metabolic syndrome may explain the increased frequency of hyperuricemia. Furthermore, recent case series reported that the prevalence of metabolic syndrome was high among patients with gout (82% in Mexican men [12] and 44% in Korean men [13] compared with 5% in the Korean general population [14]). Although these hospital-based case series (12,13) may have included patients who are sicker than individuals from the general population, the totality of available information points toward a strong link between gout and metabolic syndrome.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, recent case series reported that the prevalence of metabolic syndrome was high among patients with gout (82% in Mexican men [12] and 44% in Korean men [13] compared with 5% in the Korean general population [14]). Although these hospital-based case series (12,13) may have included patients who are sicker than individuals from the general population, the totality of available information points toward a strong link between gout and metabolic syndrome. Because the serious implications of metabolic syndrome for overall health of individuals with gout are substantial, we determined the prevalence of the syndrome among patients with gout and examined the association between the 2 conditions based on the Third National Health and Nutrition Examination Survey (NHANES-III).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey

Choi¹,

Ford²,

Li³

et al. 2007

Arthritis & Rheumatism

413

216

View full text Add to dashboard Cite

Objective. To determine the prevalence of metabolic syndrome among patients with gout and to examine the association between the 2 conditions in a nationally representative sample of US adults. Methods. Using data from 8,807 participants age >20 years in the Third National Health and Nutrition Examination Survey (1988 -1994), we determined the prevalence of metabolic syndrome among individuals with gout and quantified the magnitude of association between the 2 conditions. We used both the revised and original National -4.61), respectively. With the original NCEP/ATP criteria, the corresponding prevalences were slightly lower, whereas the corresponding odds ratios were slightly higher. The stratified prevalences of metabolic syndrome by major associated factors of gout (i.e., body mass index, hypertension, and diabetes) remained substantially and significantly higher among those with gout than those without gout (all P values <0.05). Conclusion. These findings indicate that the prevalence of metabolic syndrome is remarkably high among individuals with gout. Given the serious complications associated with metabolic syndrome, this frequent comorbidity should be recognized and taken into account in long-term treatment and overall health of individuals with gout.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey

Choi¹,

Ford²,

Li³

et al. 2007

Arthritis & Rheumatism

413

216

View full text Add to dashboard Cite

show abstract

“…[8,[16][17][18][19][20]. Однако частота выяв-ления отдельных заболеваний в разных группах больных по-дагрой может существенно различаться.…”

Section: Discussionunclassified

The Rate of Metabolic Syndrome and Comorbidities in Patients With Gout: Data of a Multicenter Trial

Барскова¹,

Eliseyev²,

Денисов³

et al. 2012

rsp

View full text Add to dashboard Cite

“…Кроме того, на течение подагры могут влиять наличие коморбидных, или сочетанных, заболеваний (СЗ) и мета-болических нарушений, частота которых у больных пода-грой крайне высока [9,10]. Однако как влияют снижение массы тела или артериального давления, улучшение пока-зателей липидного обмена на уровень МК в крови и ча-стоту приступов артрита у больных подагрой, неизвестно.…”

Section: контактная информацияunclassified

Time course of changes in the clinical manifestations of gout in men: Data of a 7-year retrospective follow-up

2015

Ter. arkh.

View full text Add to dashboard Cite

РезюмеЦель исследования. Оценка динамики клинических проявлений подагры и факторов, влияющих на них, при длительном наблюдении. Материалы и методы. Обследовали 160 больных подагрой мужчин, средний период наблюдения за которыми составил 6,9±2 года. Клиническая оценка включала определение в динамике варианта артрита, частоты приступов артрита за предшествующий осмотру год, наличия и количества подкожных тофусов, воспаленных суставов, коморбидных, или сочетанных, заболеваний (СЗ), соблюдение схемы приема аллопуринола, диеты, частоты приема нестероидных противовоспалительных препаратов, диуретиков, алкоголя. Определяли в сыворотке крови уровни мочевой кислоты (МК), глюкозы, общего холестерина, рассчитывали скорость клубочковой фильтрации. Результаты. Число больных, принимавших аллопуринол, увеличилось с 19 до 64% (р<0,0001), средняя суточная доза составила 167,6±94,6 мг. Уровень МК в сыворотке крови снизился, целевой уровень достигнут у 16% больных. Число больных хроническим артритом достоверно не изменилось. Уровень МК в сыворотке крови у них не изменился, увеличилась частота выявления подкожных тофусов, СЗ. Приступы артрита в течение года отсутствовали у 13% больных, 90% из них принимали аллопуринол. У этих больных достоверно снизились уровень МК в сыворотке крови и индекс массы тела, частота СЗ не изменилась. Ни у одного из 18 больных, соблюдавших диету и не принимавших аллопуринол, целевой уровень МК не достигнут. Заключение. Среди больных подагрой 36% воздерживаются от приема аллопуринола, только 23% из них подбирают дозу препарата до достижения целевого уровня МК. Соблюдения диеты недостаточно для достижения целевого уровня МК. Наличие хронического артрита ассоциируется с увеличением частоты развития СЗ.Ключевые слова: мочевая кислота, подагра, хронический артрит, ремиссия. Aim.To estimate the time course of changes in the clinical manifestations of gout and their risk factors during a long-term follow-up. Subjects and methods. A total of 160 male patients with gout were examined and followed up for a mean of 6.9±2.0 years. Their clinical assessment included determination of the type of arthritis over time, the frequency of arthritis attacks during one year prior to the examination, the presence and number of subcutaneous tophi, inflamed joints, comorbid or co-occurring diseases (CD), allopurinol adherence, dietary compliance, frequency of taking non-steroidal anti-inflammatory drugs (NSAIDs), diuretics, and alcohol. The serum levels of uric acid (UA), glucose, total cholesterol, and glomerular filtration rate were estimated. Results. The number of patients taking allopurinol increased from 19% to 64% (р<0.0001), its average daily dose was 167.6±94.6 mg. The serum level of UA decreased; 16% of the patients achieved its target level. The number of patients with chronic arthritis was not significantly changed. Their serum level of UA was unchanged; the detection rate of subcutaneous tophi and CD rose. During one year, arthritis attacks were absent in 13% of the patients; 90% of them took allopurinol. In these pa...

show abstract

Metabolic Syndrome and Ischemic Heart Disease in Gout

Cited by 60 publications

References 20 publications

Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey

Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey

The Rate of Metabolic Syndrome and Comorbidities in Patients With Gout: Data of a Multicenter Trial

Time course of changes in the clinical manifestations of gout in men: Data of a 7-year retrospective follow-up

Contact Info

Product

Resources

About